{
    "info": {
        "nct_id": "NCT06191796",
        "official_title": "A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.",
        "inclusion_criteria": "1. Participants with unresectable advanced or metastatic disease or 1L or 2L+ clear cell Renal cell carcinoma.\n2. Have not received HIF-2α targeted therapy previously.\n3. Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; Eisenhauer et al, 2009) as determined by the Investigator.\n4. For all participants, archival tumor tissue material should be obtained; if archival tissue is not available or is older than 2 years, then a fresh biopsy should be obtained, if medically feasible. Specific requirements for tumor tissue samples will be described in the Laboratory Manual.\n5. Recovery to baseline or ≤ Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.\n6. Karnofsky Performance Status (KPS) ≥70%.\n7. Screening ambulatory oxygen saturation (SpO2) ≥92%.\n8. Screening left ventricular ejection fraction (LVEF) above the institutional lower limit of normal.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Participants who have been previously treated with a HIF-2α targeted therapy and/or zanzalintinib.\n2. Radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Participants with clinically-relevant ongoing complications from prior radiation therapy are not eligible.\n3. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.\n4. Concomitant anticoagulation with oral anticoagulants except for 1) prophylactic use of low-dose aspirin for cardioprotection or low dose low molecular weight heparins (LMWH) or 2) therapeutic doses of LMWH or specified direct factor Xa inhibitors.\n5. Administration of a live, attenuated vaccine within 30 days prior to enrollment.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "8. Screening left ventricular ejection fraction (LVEF) above the institutional lower limit of normal.",
            "criterions": [
                {
                    "exact_snippets": "Screening left ventricular ejection fraction (LVEF) above the institutional lower limit of normal",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "institutional lower limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; Eisenhauer et al, 2009) as determined by the Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; Eisenhauer et al, 2009)",
                    "criterion": "measurable disease (per RECIST 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Recovery to baseline or ≤ Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.",
            "criterions": [
                {
                    "exact_snippets": "Recovery to baseline or ≤ Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from AE(s) related to any prior treatments",
                    "criterion": "adverse events (AEs) related to any prior treatments",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "recovered to baseline"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless AE(s) are deemed clinically nonsignificant by the Investigator",
                    "criterion": "adverse events (AEs) related to any prior treatments",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": "nonsignificant (as deemed by Investigator)"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless AE(s) are ... stable on supportive therapy",
                    "criterion": "adverse events (AEs) related to any prior treatments",
                    "requirements": [
                        {
                            "requirement_type": "stability on supportive therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Karnofsky Performance Status (KPS) ≥70%.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky Performance Status (KPS) ≥70%",
                    "criterion": "Karnofsky Performance Status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Have not received HIF-2α targeted therapy previously.",
            "criterions": [
                {
                    "exact_snippets": "Have not received HIF-2α targeted therapy previously",
                    "criterion": "HIF-2α targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. For all participants, archival tumor tissue material should be obtained; if archival tissue is not available or is older than 2 years, then a fresh biopsy should be obtained, if medically feasible. Specific requirements for tumor tissue samples will be described in the Laboratory Manual.",
            "criterions": [
                {
                    "exact_snippets": "archival tumor tissue material should be obtained",
                    "criterion": "archival tumor tissue material",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if archival tissue is not available or is older than 2 years, then a fresh biopsy should be obtained, if medically feasible",
                    "criterion": "fresh biopsy",
                    "requirements": [
                        {
                            "requirement_type": "necessity condition",
                            "expected_value": "if archival tissue is not available or is older than 2 years"
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "medical feasibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Specific requirements for tumor tissue samples will be described in the Laboratory Manual",
                    "criterion": "tumor tissue samples",
                    "requirements": [
                        {
                            "requirement_type": "requirements location",
                            "expected_value": "Laboratory Manual"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants with unresectable advanced or metastatic disease or 1L or 2L+ clear cell Renal cell carcinoma.",
            "criterions": [
                {
                    "exact_snippets": "unresectable advanced or metastatic disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "unresectable advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "1L or 2L+ clear cell Renal cell carcinoma",
                    "criterion": "clear cell Renal cell carcinoma treatment line",
                    "requirements": [
                        {
                            "requirement_type": "treatment line",
                            "expected_value": [
                                "1L",
                                "2L+"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Screening ambulatory oxygen saturation (SpO2) ≥92%.",
            "criterions": [
                {
                    "exact_snippets": "Screening ambulatory oxygen saturation (SpO2) ≥92%",
                    "criterion": "ambulatory oxygen saturation (SpO2)",
                    "requirements": [
                        {
                            "requirement_type": "value at screening",
                            "expected_value": {
                                "operator": ">=",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "4. Concomitant anticoagulation with oral anticoagulants except for 1) prophylactic use of low-dose aspirin for cardioprotection or low dose low molecular weight heparins (LMWH) or 2) therapeutic doses of LMWH or specified direct factor Xa inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "Concomitant anticoagulation with oral anticoagulants except for 1) prophylactic use of low-dose aspirin for cardioprotection or low dose low molecular weight heparins (LMWH) or 2) therapeutic doses of LMWH or specified direct factor Xa inhibitors.",
                    "criterion": "concomitant anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "medication type",
                            "expected_value": "oral anticoagulants"
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "prophylactic use of low-dose aspirin for cardioprotection",
                                "low dose low molecular weight heparins (LMWH)",
                                "therapeutic doses of LMWH",
                                "specified direct factor Xa inhibitors"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Administration of a live, attenuated vaccine within 30 days prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Administration of a live, attenuated vaccine within 30 days prior to enrollment.",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Known brain metastases or cranial epidural disease",
                    "criterion": "brain metastases or cranial epidural disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless adequately treated with radiotherapy and/or surgery (including radiosurgery)",
                    "criterion": "treatment of brain metastases or cranial epidural disease",
                    "requirements": [
                        {
                            "requirement_type": "adequate treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment modalities",
                            "expected_value": [
                                "radiotherapy",
                                "surgery",
                                "radiosurgery"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "stable for at least 4 weeks before first dose of study treatment",
                    "criterion": "stability of brain metastases or cranial epidural disease after treatment",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants who have been previously treated with a HIF-2α targeted therapy and/or zanzalintinib.",
            "criterions": [
                {
                    "exact_snippets": "previously treated with a HIF-2α targeted therapy",
                    "criterion": "prior HIF-2α targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with ... zanzalintinib",
                    "criterion": "prior zanzalintinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "2. Radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Participants with clinically-relevant ongoing complications from prior radiation therapy are not eligible.",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy for bone metastases within 2 weeks before first dose of study treatment",
                    "criterion": "radiation therapy for bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other radiation therapy within 4 weeks before first dose of study treatment",
                    "criterion": "other radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically-relevant ongoing complications from prior radiation therapy",
                    "criterion": "ongoing complications from prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}